|
|
 |
 |
104. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft 2006
Abstract
Abstract
SA.04.08 Retinal pigment epithelial tear after intravitreal injection of bevacizumab (Avastin) in a series of patients with neovascular age-related macular degeneration Kook D., Wolf A., Priglinger S., Haritoglou C., Hofer A., Strauß R., Gandorfer A., Ulbig M., Kampik A.
Department of Ophthalmology of the Ludwig-Maximilians-University Munich Objective: To report about retinal pigment epithelial (RPE) tear associated with intravitreal injection of bevacizumab in 5 patients with neovascular age related macular degeneration (AMD).
Methods: In the scope of a clinical observational study between October 2005 and February 2006 184 patients with neovascular AMD received at least one intravitreal injection of bevacizumab and were followed with sequential ETDRS-visual acuity testing, fundus photography, fluorescein angiography, and optical coherence tomography in our department.
Results: Five patients developed a RPE tear between 2-8 weeks after intravitreal injection of 1,0 mg bevacizumab. In all patients pigment epithelial detachment (PED) was the underlying type of neovascular AMD. The temporal course suggests that the injection of the VEGF antagonist led to stretching forces along the RPE with a consecutive secondary RPE rupture.
Conclusions: Intravitreal injection of VEGF antagonists like bevacizumab has been shown to be an effective treatment in different types of neovascular AMD. Based on the observations of this series larger RPE detachments might be excluded from an injection of VEGF antagonists due to the sensible nature of the RPE monolayer in neovascular AMD.
Zurück | Back
|
